Contents: Doxorubicin

Indication/Uses: Listed in Dosage.

Dosage/Direction for Use: Adult : IV AIDS-related Kaposi's sarcoma As pegylated liposome: 20 mg/m2 once 2-3 wkly. Ovarian carcinoma As pegylated liposome: 50 mg/m2 once 4 wkly. Metastatic breast carcinoma w/ cyclophosphamide: 60-75 mg/m2 once 3 wkly. Irrigation Local malignant neoplasms in the bladder As 1 mg/mL soln: Instill 50 mL into the bladder for 1 hr once monthly.

Overdosage: Acute overdosage may increase the toxic effects of mucositis, leukopenia and thrombocytopenia. Treatment includes hospitalisation of the severely myelosuppressed patient, antimicrobials, platelet transfusions and symptomatic treatment of mucositis. Use of haemopoietic growth factor (G-CSF, GM-CSF) may be considered. Cumulative dosage increases risk of cardiomyopathy and resultant congestive heart failure which may be managed with digitalis preparations, diuretics, and after load reducers such as ACE inhibitors.

Drug Interactions: 

Doxorubicin interacts with a number of other drugs e.g. antibiotics (aminoglycosides), steroids, aminophylline and propranolol.

Potentially Fatal: Cholestasis induced by mercaptopurine may be potentiated by concurrent administration of the drug. Toxicity may be increased if streptozocin is given concurrently.

Drug Interactions: 

Doxorubicin interacts with a number of other drugs e.g. antibiotics (aminoglycosides), steroids, aminophylline and propranolol.

Potentially Fatal: Cholestasis induced by mercaptopurine may be potentiated by concurrent administration of the drug. Toxicity may be increased if streptozocin is given concurrently.

Storage: Powder for inj: Store at 15-30°C. Solution for inj & liposomal formulations: Refrigerate at 2-8°C. Do not freeze.